Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer's Disease: A Comparison of the Cognitive and Clinical Profiles
Overview
Neurology
Affiliations
Background: Dementia must be diagnosed accurately and early in the disease course to allow pathology-specific treatments to be effective. Dementia with Lewy bodies (DLB) is often misdiagnosed as Alzheimer's disease (AD), especially at the prodromal stage.
Objective: To compare the clinical and neuropsychological profiles of Mild Cognitive Impairment (MCI) patients who, at follow-up, progressed to AD (retrospectively AD-MCI) or DLB (retrospectively DLB-MCI) or remained MCI.
Methods: This longitudinal study used an unselected sample from a memory clinic database. A total of 1,848 new patients were seen at the memory clinic between 1994-2015. Of these, 560 patients (30%) had an initial diagnosis of MCI and were considered for the study. Inclusion criteria were patients who had a diagnosis of MCI at initial assessment and a minimum of 12 months' follow-up.
Results: Of the 429 MCI patients with follow-up data, 164 (38%) remained MCI, 107 (25%) progressed to AD, and 21 (5%) progressed to DLB. The remainder progressed to alternative diagnoses. At baseline, DLB-MCI patients performed significantly worse on visuospatial function and letter fluency tests than both AD-MCI and stable-MCI groups, and better on episodic memory tests than the AD-MCI group. At baseline, DLB-MCI patients had a significantly higher mean UPDRS score and were more likely to have REM sleep behavior disorder and fluctuating cognition.
Conclusion: DLB-MCI patients have a specific cognitive and neuropsychiatric profile which should alert clinicians to the possibility of prodromal DLB. This is relevant when considered in the context of early disease-specific therapy.
Wyman-Chick K, Bayram E, Gravett S, DAntonio F, Rodriguez-Porcel F, Kane J Alzheimers Dement. 2025; 21(2):e14450.
PMID: 39791487 PMC: 11848198. DOI: 10.1002/alz.14450.
Busse C, Mitolo M, Mozzetta S, Venneri A, Cagnin A Front Psychiatry. 2024; 15:1461620.
PMID: 39720441 PMC: 11666550. DOI: 10.3389/fpsyt.2024.1461620.
Whitfield T, Chouliaras L, Morrell R, Rubio D, Radford D, Marchant N Alzheimers Res Ther. 2024; 16(1):142.
PMID: 38943160 PMC: 11212190. DOI: 10.1186/s13195-024-01516-6.
Wyman-Chick K, Chaudhury P, Bayram E, Abdelnour C, Matar E, Chiu S Neurol Ther. 2024; 13(3):885-906.
PMID: 38720013 PMC: 11136939. DOI: 10.1007/s40120-024-00620-x.
Stockbauer A, Beyer L, Huber M, Kreuzer A, Palleis C, Katzdobler S Eur J Nucl Med Mol Imaging. 2023; 51(4):1023-1034.
PMID: 37971501 PMC: 10881642. DOI: 10.1007/s00259-023-06493-w.